This single-patient case report describes the first use of the tyrosine kinase inhibitor STI571 (imatinib) in metastatic gastrointestinal stromal tumor (GIST). The patient had chemotherapy-refractory disease driven by a c-kit exon 11 mutation. It asks whether selectively inhibiting mutant c-kit can control a tumor with no effective therapy.
This single-patient case report describes the first use of the tyrosine kinase inhibitor STI571 (imatinib) in metastatic gastrointestinal stromal tumor (GIST). The patient had chemotherapy-refractory disease driven by a c-kit exon 11 mutation. It asks whether selectively inhibiting mutant c-kit can control a tumor with no effective therapy.